replacement. The suggested subanalysis is undoubtly appropriate and we did in fact find a trend towards a faster decline in left ventricular mass in pure aortic stenosis patients after aortic valve replacement with the Trifecta bioprosthesis. However, our study is underpowered for that matter and this could, therefore, at most, be a question for future works.
REFERENCES [1] We read with great interest the article by Falk et al. [1] regarding guidelines of management strategies for an individual patient with a given valvular disease. We do believe that the recommendation that favours transcatheter aortic valve implantation (TAVI) versus surgical aortic valve replacement (SAVR) in patients with an European System for Cardiac Operative Risk Evaluation II (EuroSCORE) value > _4% (increased surgical risk, according to the authors, Table 7 . and table on page 631) needs further clarification and discussion. In particular, until recently, no threshold value has been proposed for the EuroSCORE II to define high-risk patients [2] . To the best of our knowledge, Arangalage et al. [3] are the only researchers who have searched for correspondence between borderline values of the Society of Thoracic Surgeons (STS) score and old logistic EuroSCORE for high-risk patients (> _10% and > _20%, respectively), which favour TAVI, and for the EuroSCORE II. They proposed a threshold of > _7% for high-risk patients, which provided the best diagnostic value in their research cohort. In a subanalysis of our patients [2] undergoing SAVR (979 patients), 950 patients had a EuroSCORE II of <10%, and mortality was as low as 1.47% (14 of 950, predicted mortality 1.93%). Leon et al. [4] in a prospective, randomized study (2302 patients, with 81.3% of them with an STS score of between 4.0% and 8.0%, 30day mortality 6.1% for TAVI, 8.0% for SAVR, P-value = 0.11) concluded that in intermediate-risk patients, TAVI was similar to SAVR with respect to the primary end point of death or disabling stroke at 2 years. Therefore, is it rational to favour TAVI over SAVR in all patients with an STS or EuroSCORE II value of > _4%?
The European Society of Cardiology/European Association for Cardio-Thoracic Surgery (ESC/EACTS) guidelines on valvular heart disease [1] provide guidance for the diagnostic workup for patients with aortic stenosis and give recommendations for appropriate treatment strategies. Since the last version of the guideline in 2012, a huge amount of new evidence has been generated with regard to the risks and benefits of surgical aortic valve replacement and interventional transcatheter aortic valve implantation (TAVI) treatment for severe aortic stenosis. Although for inoperable patients and patients with high surgical risk TAVI has evolved as the therapy of choice if no anatomical or technical criteria render a transcatheter approach impossible, for intermediate risk patients, the available studies demonstrate equipoise with regard to the primary outcome.
